Pfizer seeks to boost Prevnar 13 use in adults with CAPiTA data
By Marie Powers
Monday, February 24, 2014
Pfizer Inc.’s blockbuster vaccine, Prevnar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), could be poised for a big boost. Pfizer reported that its CAPiTA study met its primary endpoint.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.